This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-06 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Domestic politics === On the outbreak of war, Huggins invited the leader of the opposition Labour Party, Harry Davies, to join a coalition government. Davies accepted without consulting his party caucus, much to the indignation of many of his contemporaries; Labour promptly split. The two Labour factions reconciled in 1943 and briefly threatened Huggins's premiership until a heated dispute over whether Labour should become multiracial led to the party's disintegration in 1944.
During the show's ninth season, which has subsequently been entirely retconned out of the series continuity, Bev comes out as a lesbian (according to one of Roseanne's fictional twists on her family, along with winning the lottery). In the finale, Roseanne states that it is her sister, Jackie, not Bev, who is a lesbian. This has also been retconned out of the series continuity. From what is known of Bev's childhood and marriage, her life was emotionally difficult, plagued with instability and neglect. Her unrestrained mother Mary put her personal freedom ahead of her children. As a result of her promiscuity, Mary is uncertain about who Bev's father was. As a young woman, Bev found herself pregnant out of wedlock, as her mother had been. Unlike her mother, Bev married her baby's father, Al Harris. Their marriage lasted several decades, but Al treated their two daughters harshly and cheated on Bev, having a secret mistress for twenty years. Disappointed in her life, Bev grew bitter in her old age, making her critical of others. Bev returned in season 10 of Rosanne, and in the subsequent follow-up series The Conners. In season 10 of Roseanne, Bev was kicked out of her retirement community for sleeping with others and spreading STIs; Jackie and Roseanne alternated keeping care of her at their respective homes.
== CART as a marker of optic nerve head astrocytes == Much of the current knowledge about astrocyte morphology and function has been derived from studies of gray matter protoplasmic astrocytes, while white matter fibrous astrocytes remain less characterized. A transcriptomic study using the RiboTag approach or Ribosome profiling, analyzed ribosome-associated mRNA from uninjured fibrous astrocytes in three regions: the unmyelinated optic nerve head, the myelinated optic nerve proper, and the corpus callosum. The analysis revealed that astrocytes from each region were transcriptionally distinct, with region-specific gene expression patterns and pathways. Differences in energy metabolism, particularly oxidative phosphorylation and mitochondrial protein translation, were identified as major distinguishing features. Optic nerve astrocytes also showed elevated expression of neuroinflammatory pathways compared to corpus callosum astrocytes. The study further identified CART prepropeptide as a novel marker of optic nerve head astrocytes, highlighting the functional diversity and heterogeneity of white matter astrocyte populations beyond what was previously recognized.
== Diagnosis == Screening for muscle atrophy is limited by a lack of established diagnostic criteria, although many have been proposed. Diagnostic criteria for other conditions such as sarcopenia or cachexia can be used. These syndromes can also be identified with screening questionnaires. Muscle mass and changes can be quantified on imaging studies such as CT scans or Magnetic resonance imaging (MRI). Biomarkers such as urine urea can be used to roughly estimate muscle loss during circumstances of rapid muscle loss. Other biomarkers are currently under investigation but are not used in clinical practice.
==== 2600–2699 ==== Greater Manchester Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2600) Lancashire Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2601) Tameside and Glossop Acute Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2602) Darlington Memorial Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2603) Bolton Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2604) Priority Healthcare Wearside National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2605) Community Health Care Service (North Derbyshire) National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2606) Wirral Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2607) North Lakeland Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2608) North Downs Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2609) South Durham Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2610) Salford Community Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2611) Community Health Care: North Durham National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2612) Kingston and District Community National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2613) North Durham Acute Hospitals National Health Service Trust (Establishment) Order 1993 (S.I.
Sources: en.wikipedia.org
Polystyrene packing peanuts are inexpensive, readily available, and have excellent drainage. However, they can be too lightweight for some uses. They are used mainly in closed-tube systems. Note that non-biodegradable polystyrene peanuts must be used; biodegradable packing peanuts will decompose into a sludge. Plants may absorb styrene and pass it to their consumers; this is a possible health risk.
In the dominant post-war narrative of West Germany, the Nazi regime was characterised as having been a 'criminal' state, illegal and illegitimate from the outset; while the Weimar Republic was characterised as having been a 'failed' state, whose inherent institutional and constitutional flaws had been exploited by Hitler in his illegal seizure of dictatorial powers. Consequently, following the death of Hitler in 1945 and the subsequent capitulation of the German Armed Forces, the national political, judicial, administrative, and constitutional instruments of both Nazi Germany and the Weimar Republic were understood as entirely defunct, such that a new West Germany could be established in a condition of constitutional nullity. Nevertheless, the new West Germany asserted its fundamental continuity with the 'overall' German state that was held to have embodied the unified German people since the Frankfurt Parliament of 1848, and which from 1871 had been represented within the German Reich; albeit that this overall state had become effectively dormant long before 8 May 1945. In 1949 with the continuation and aggravation of the Cold War (for example, the Berlin Airlift of 1948–49), the two German states that had originated in the Western Allied and the Soviet Zones respectively became known internationally as West Germany and East Germany. Commonly known in English as East Germany, the former Soviet occupation zone in Germany, eventually became the German Democratic Republic or GDR.
==== MeSH D12.776.664.962.444 – mrna cleavage and polyadenylation factors ==== MeSH D12.776.664.962.444.240 – cleavage and polyadenylation specificity factor MeSH D12.776.664.962.444.249 – cleavage stimulation factor
Seborrhoeic dermatitis typically appears as oily, yellowish, flaky skin. Although commonly associated with oily skin, it can also appear on dry scalps or skin, where the flaking may look similar to dandruff. Flakes can be fine, loose, and diffuse; or they can be thick and adherent. In addition to flaky skin, seborrhoeic dermatitis can have areas of red, rashy, inflamed, and itchy skin that coincide with the area of skin flaking, but not all individuals have this symptom. Seborrhoeic dermatitis of the scalp can appear similarly to dandruff. When the scalp is affected, there can be associated temporary hair loss. Such hair loss varies in appearance from diffuse thinning to patchy areas of hair loss. On close inspection, the locations where hair has thinned may have broken stubs of hair and pustules around the hair follicles. Individuals with more pigmented skin tones may experience increased or decreased skin pigmentation in affected areas. Various locations can be affected by seborrhoeic dermatitis. Commonly affected areas include the face, ears, scalp, and across the body. It is less common in intertriginous areas, which are areas where the skin folds and comes into contact with itself, such as the groin or the underarms. Seborrhoeic dermatitis' symptoms are typically mild and appear gradually but are often persistent, lasting weeks to years. Individuals with seborrhoeic dermatitis are subject to recurrent bouts and it may be a lifelong condition. Seborrhoeic dermatitis can also occur quickly and severely in patients with Human Immunodeficiency Virus (HIV).
Sources: en.wikipedia.org
facilitated the passage of the federal Civil Rights Act of 1968, which included fair housing, so the Detroit riot of July 1967, 'the worst racial disturbance' of the century to that time, provided the impetus for the passage of Michigan's fair housing law as well as similar measures in many Michigan communities." Other laws passed in response to the disorder included "important relocation, tenants' rights, and code enforcement legislation". Governor Romney had made such proposals throughout the 1960s, but the opposition did not collapse until after the riot.
This was famously experienced by mountaineer Beck Weathers (who had undergone RK) during the 1996 Mount Everest disaster. Diurnal fluctuation: in a majority of patients who have undergone RK the cornea will steepen throughout the day. This can lead to variation in visual quality throughout the day.
Magic numbers of 2, 8, 20, 28, 50, 82 and 126 have been observed for neutrons, and the next number is predicted to be 184. Protons share the first six of these magic numbers, and 126 has been predicted as a magic proton number since the 1940s. Nuclides with a magic number of each—such as 16O (Z = 8, N = 8), 132Sn (Z = 50, N = 82), and 208Pb (Z = 82, N = 126)—are referred to as "doubly magic" and are more stable than nearby nuclides as a result of greater binding energies. In the late 1960s, more sophisticated shell models were formulated by American physicist William Myers and Polish physicist Władysław Świątecki, and independently by German physicist Heiner Meldner (1939–2019). With these models, taking into account Coulomb repulsion, Meldner predicted that the next proton magic number may be 114 instead of 126. Myers and Świątecki appear to have coined the term "island of stability", and American chemist Glenn Seaborg, later a discoverer of many of the superheavy elements, quickly adopted the term and promoted it. Myers and Świątecki also proposed that some superheavy nuclei would be longer-lived as a consequence of higher fission barriers. Further improvements in the nuclear shell model by Soviet physicist Vilen Strutinsky led to the emergence of the macroscopic–microscopic method, a nuclear mass model that takes into consideration both smooth trends characteristic of the liquid-drop model and local fluctuations such as shell effects.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.